Skip to main content
SpringerLink
Log in

AIDS-Related Plasmablastic Lymphoma

  • Chapter
  • First Online:
HIV-associated Hematological Malignancies

  • 609 Accesses

Abstract

In 1997 a new entity was added to the World Health Organization (WHO) classification of lymphomas as a subset of diffuse large B cell lymphoma (DLBCL) called plasmablastic lymphoma (PBL). Its classification was prompted by its plasmacytoid appearance, with an elevated proliferation index, post-germinal phenotype with loss of the mature B cell markers, CD20, and strong expression of mature plasma cell antigens, i.e., CD138. The initial description was that this lymphoma affects primarily mucosal sites, particularly the oropharynx, and is characterized by poor outcome and is present predominantly in patients infected with HIV, though cases have also been reported in patients with advanced age or poor immune function. Here we examine the epidemiology, pathogenesis, diagnosis, and treatments for PBL and future directions to gain insight on how to better understand and manage this entity in patients infected with HIV.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Delecluse HJ, Anagnostopoulos I, Dallenbach F, et al. Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection. Blood. 1997;89:1413–20.

    CAS  PubMed  Google Scholar 

  2. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, World Health Organization. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: International Agency for Research on Cancer; 2008.

    Google Scholar 

  3. Bibas M, Castillo JJ. Current knowledge on HIV-associated plasmablastic lymphoma. Mediterr J Hematol Infect Dis. 2014;6(1):e2014064.

    Article  PubMed Central  PubMed  Google Scholar 

  4. Castillo JJ, Bibas M, Miranda RN. The biology and treatment of plasmablastic lymphoma. Blood. 2015;125:2323–30.

    Google Scholar 

  5. Carbone A, Gloghini A, Larocca LM, Capello D, Pierconti F, Canzonieri V, Tirelli U, Dalla-Favera R, Gaidano G. Expression profile of MUM1/IRF4, BCL-6, and CD138/syndecan-1 defines novel histogenetic subsets of human immunodeficiency virus-related lymphomas. Blood. 2001;97(3):744–51.

    Article  CAS  PubMed  Google Scholar 

  6. Colomo L, Loong F, Rives S, et al. Diffuse large B-cell lymphomas with plasmablastic differentiation represent a heterogeneous group of disease entities. Am J Surg Pathol. 2004;28(6):736–47.

    Article  PubMed  Google Scholar 

  7. Teruya-Feldstein J, Chiao E, Filippa DA, Lin O, Comenzo R, Coleman M, Portlock C, Noy A. CD20-negative large-cell lymphoma with plasmablastic features: a clinically heterogenous spectrum in both HIV-positive and -negative patients. Ann Oncol. 2004;15:1673–9.

    Article  CAS  PubMed  Google Scholar 

  8. Castillo J, Pantanowitz L, Dezube BJ. HIV-associated plasmablastic lymphoma: lessons learned from 112 published cases. Am J Hematol. 2008;83:804–9.

    Article  PubMed  Google Scholar 

  9. Shiels MS, Pfeiffer RM, Gail MH, Hall HI, Li J, Chaturvedi AK, et al. Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst. 2011;103(9):753–62.

    Article  PubMed Central  PubMed  Google Scholar 

  10. Shiels MS, Pfeiffer RM, Hall HI, Li J, Goedert JJ, Morton LM, Hartge P, Engels EA. Proportions of Kaposi sarcoma, selected non-Hodgkin lymphomas, and cervical cancer in the United States occurring in persons with AIDS, 1980–2007. JAMA. 2011;305(14):1450–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  11. Guech-Ongey M, Simard EP, Anderson WF, Engels EA, Bhatia K, Devesa SS, et al. AIDS-related Burkitt lymphoma in the United States: what do age and CD4 lymphocyte patterns tell us about etiology and/or biology? Blood. 2010;116:5600–4.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  12. Magrath I. Epidemiology: clues to the pathogenesis of Burkitt lymphoma. Br J Haematol. 2012;156(6):744.

    Article  CAS  PubMed  Google Scholar 

  13. Carbone A, Gloghini A. Plasmablastic lymphoma: one or more entities? Am J Hematol. 2008;83:763–4.

    Article  PubMed  Google Scholar 

  14. Schommers P, Hentrich M, Hoffmann C, Gillor D, Zoufaly A, Jensen B, et al. Survival of AIDS-related diffuse large B-cell lymphoma, Burkitt lymphoma, and plasmablastic lymphoma in the German HIV lymphoma cohort. Br J Haematol. 2014. doi:10.1111/bjh.13221.

    PubMed  Google Scholar 

  15. Gupta S, Jain S, Sandhu S, Sreenivasappa S, Pattali S, Braik T, et al. A retrospective analysis of all hematological malignancies in patients infected with HIV, a subset analysis of the CHAMP study (Cook County Hospital (CCH) AIDS malignancy project). Blood (ASH Annu Meet Abstr). 2011;118:3693.

    Google Scholar 

  16. Castillo JJ, Winer ES, Stachurski D, Perez K, Jabbour M, Milani C, Colvin G, Butera JN. Clinical and pathological differences between human immunodeficiency virus-positive and human immunodeficiency virus-negative patients with plasmablastic lymphoma. Leuk Lymphoma. 2010;51:2047–53.

    Article  PubMed  Google Scholar 

  17. Castillo JJ, Furman M, Beltrán BE, Bibas M, Bower M, Chen W, et al. Human immunodeficiency virus-associated plasmablastic lymphoma: poor prognosis in the era of highly active antiretroviral therapy. Cancer. 2012;118(21):5270–7.

    Article  PubMed  Google Scholar 

  18. Chang H, Samiee S, Yi QL. Prognostic relevance of CD56 expression in multiple myeloma: a study including 107 cases treated with high-dose melphalan-based chemotherapy and autologous stem cell transplant. Leuk Lymphoma. 2006;47(1):43–7.

    Article  CAS  PubMed  Google Scholar 

  19. Vega F, Chang CC, Medeiros LJ, Udden MM, Cho-Vega JH, Lau CC, Finch CJ. Plasmablastic lymphomas and plasmablastic plasma cell myelomas have nearly identical immunophenotypic profiles. Mod Pathol. 2005;18(6):806–15.

    Article  PubMed  Google Scholar 

  20. Rubinstein PG, Aboulafia DM, Zloza A. Malignancies in HIV/AIDS: from epidemiology to therapeutic challenges. AIDS. 2014;28(4):453–65.

    Article  PubMed Central  PubMed  Google Scholar 

  21. Folk GS, Abbondanzo SL, Childers EL, Foss RD. Plasmablastic lymphoma: a clinicopathologic correlation. Ann Diagn Pathol. 2006;10(1):8–12.

    Article  PubMed  Google Scholar 

  22. Bogusz AM, Seegmiller AC, Garcia R, Shang P, Ashfaq R, Chen W. Plasmablastic lymphomas with MYC/IgH rearrangement: report of three cases and review of the literature. Am J Clin Pathol. 2009;132(4):597–605.

    Article  CAS  PubMed  Google Scholar 

  23. Taddesse-Heath L, Meloni-Ehrig A, Scheerle J, Kelly JC, Jaffe ES. Plasmablastic lymphoma with MYC translocation: evidence for a common pathway in the generation of plasmablastic features. Mod Pathol. 2010;23(7):991–9.

    Article  PubMed  Google Scholar 

  24. Valera A, Balague O, Colomo L, et al. IG/MYC rearrangements are the main cytogenetic alteration in plasmablastic lymphomas. Am J Surg Pathol. 2010;34(11):1686–94.

    PubMed Central  PubMed  Google Scholar 

  25. Ott G, Rosenwald A, Campo E. Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification. Blood. 2013;122(24):3884–91.

    Article  CAS  PubMed  Google Scholar 

  26. McLaughlin-Drubin ME, Munger K. Viruses associated with human cancer. Biochim Biophys Acta. 2008;1782:127–50.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  27. Ambinder RF. Epstein-Barr virus associated lymphoproliferations in the AIDS setting. Eur J Cancer. 2001;37:1209–16.

    Article  CAS  PubMed  Google Scholar 

  28. Carbone A, Tirelli U, Gloghini A, Volpe R, Boiocchi M. Human immunodeficiency virus-associated systemic lymphomas may be subdivided into two main groups according to Epstein-Barr viral latent gene expression. J Clin Oncol. 1993;11:1674–81.

    CAS  PubMed  Google Scholar 

  29. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136:215–33.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  30. Qi P, Han JX, Lu YQ, Wang C, Bu FF. Virus-encoded microRNAs: future therapeutic targets? Cell Mol Immunol. 2006;3:411–9.

    CAS  PubMed  Google Scholar 

  31. Yeung ML, Bennasser Y, Le SY, Jeang KT. siRNA, miRNA and HIV: promises and challenges. Cell Res. 2005;15:935–46.

    Article  CAS  PubMed  Google Scholar 

  32. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435:834–8.

    Article  CAS  PubMed  Google Scholar 

  33. Pfeffer S, Voinnet O. Viruses, microRNAs and cancer. Oncogene. 2006;25:6211–9.

    Article  CAS  PubMed  Google Scholar 

  34. Montes-Moreno S, Gonzalez-Medina AR, Rodriguez-Pinilla SM, et al. Aggressive large B-cell lymphoma with plasma cell differentiation: immunohistochemical characterization of plasmablastic lymphoma and diffuse large B-cell lymphoma with partial plasmablastic phenotype. Haematologica. 2010;95(8):1342–9.

    Article  PubMed Central  PubMed  Google Scholar 

  35. Schmelz M, Montes-Moreno S, Piris M, et al. Lack and/or aberrant localization of major histocompatibility class II (MHCII) protein in plasmablastic lymphoma. Haematologica. 2012;97(10):1614–6.

    Article  PubMed Central  PubMed  Google Scholar 

  36. Hart LS, Cunningham JT, Datta T, et al. ER stress-mediated autophagy promotes myc-dependent transformation and tumor growth. J Clin Invest. 2012;122(12):4621–34.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  37. Avet-Loiseau H, Gerson F, Magrangeas F, et al. Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors. Blood. 2001;98(10):3082–6.

    Article  CAS  PubMed  Google Scholar 

  38. Noy A, Cahdburn A, Lensing SY, Moore P. Plasmablastic lymphoma is curable the HAART Era. A 10 year retrospective by the AIDS malignancy consortium (AMC). American Society of Hematology National meeting. Blood. 2013;122:1801.

    Google Scholar 

  39. Ibrahim IF, Shapiro GA, Naina HVK. Treatment of HIV-associated plasmablastic lymphoma: a single-center experience with 25 patients. J Clin Oncol. 2014;32:5s. suppl; abstr 8583.

    Article  Google Scholar 

  40. Lee LX, Konda B, Assal A, Zell MI, Braunshweig I, Derman O, et al. Plasmablastic lymphoma: a case series of the changing epidemiology of a rare extramedullary plasmacytoid neoplasm, diagnostic challenges, and therapeutic implications. Blood. 2014;124:2995.

    Google Scholar 

  41. Schommers P, Wyen C, Hentrich M, Gillor D, Zoufaly A, Jensen B, et al. Poor outcome of HIV-infected patients with plasmablastic lymphoma: results from the German AIDS-related lymphoma cohort study. AIDS. 2013;27(5):842–5.

    Article  PubMed  Google Scholar 

  42. Barta SK, Xue X, Wang D, Tamari R, Lee JY, Mounier N, Kaplan LD, et al. Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients. Blood. 2013;122(19):3251–62.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  43. Castillo JJ, Winer ES, Stachurski D, Perez K, Jabbour M, Milani C, et al. Prognostic factors in chemotherapy-treated patients with HIV-associated plasmablastic lymphoma. Oncologist. 2010;15(3):293–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  44. Reid EG. Bortezomib-induced Epstein-Barr virus and Kaposi sarcoma herpesvirus lytic gene expression: oncolytic strategies. Curr Opin Oncol. 2011;23(5):482–7.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  45. Hui KF, Ho DN, Tsang CM, Middeldorp JM, Tsao GS, Chiang AK. Activation of lytic cycle of Epstein-Barr virus by suberoylanilide hydroxamic acid leads to apoptosis and tumor growth suppression of nasopharyngeal carcinoma. Int J Cancer. 2012;131(8):1930–40.

    Article  CAS  PubMed  Google Scholar 

  46. Moreau P, Richardson PG, Cavo M, Orlowski RZ, San Miguel JF, Palumbo A, et al. Proteasome inhibitors in multiple myeloma: 10 years later. Blood. 2012;120(5):947–59.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  47. Dunleavy K, Pittaluga S, Czuczman MS, Dave SS, Wright G, Grant N, et al. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood. 2009;113:6069–76.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  48. Copeland A, Buglio D, Younes A. Histone deacetylase inhibitors in lymphoma. Curr Opin Oncol. 2010;22(5):431–6.

    Article  CAS  PubMed  Google Scholar 

  49. https://clinicaltrials.gov/ct2/show/NCT00598169?term=aids+malignancy+consortium&rank=20.

  50. https://clinicaltrials.gov/ct2/show/NCT01193842?term=amc+075&rank=1.

  51. Bhatt V1, Alejandro L, Michael A, Ganetsky A. The promising impact of ibrutinib, a Bruton’s tyrosine kinase inhibitor, for the management of lymphoid malignancies. Pharmacotherapy. 2014;34:303–14.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section of Hematology/Oncology, Department of Medicine, John H. Stroger Jr. Hospital of Cook County (Cook County Hospital), Chicago, IL, USA

    Paul G. Rubinstein MD

  2. Rush University Medical Center, Chicago, IL, USA

    Paul G. Rubinstein MD

  3. The Ruth M. Rothstein CORE Center, Chicago, IL, USA

    Paul G. Rubinstein MD

  4. First Department of Internal Medicine, University of Cologne, Cologne, Germany

    Christoph Wyen MD

Authors
  1. Paul G. Rubinstein MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christoph Wyen MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paul G. Rubinstein MD .

Editor information

Editors and Affiliations

  1. Department of Hematology and Oncology, Red Cross Hospital, Uni of Munich, Munich, Germany

    Marcus Hentrich

  2. Dept. of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA

    Stefan K. Barta

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Rubinstein, P.G., Wyen, C. (2016). AIDS-Related Plasmablastic Lymphoma. In: Hentrich, M., Barta, S. (eds) HIV-associated Hematological Malignancies. Springer, Cham. https://doi.org/10.1007/978-3-319-26857-6_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-26857-6_5

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-26855-2

  • Online ISBN: 978-3-319-26857-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation